AbbVie, Inc. (ABBV)

112.62
0.44 0.39
NYSE
Prev Close 112.18
Open 112.91
Day Low/High 111.47 / 113.10
52 Wk Low/High 62.55 / 113.41
Volume 6.55M
Exchange NYSE
Shares Outstanding 1765.47B
Market Cap 195.12B
P/E Ratio 89.85
Div & Yield N.A. (N.A)
Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

Abbvie downgraded at Credit Suisse

AbbVie Q3 Revenue Misses, Shares Decline

AbbVie Q3 Revenue Misses, Shares Decline

Shares of AbbVie were lower Friday after posting disappointing third-quarter revenue.

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Technology stocks dominate the bearish ledger this week.

Time For Selective Purchases of Health-Care Stocks

Time For Selective Purchases of Health-Care Stocks

With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.

These Dogs Are Becoming Cool Cats

These Dogs Are Becoming Cool Cats

The dreck of the first half will be the gems of year end.

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

Dive Safely Into These 12 Dividend Payers

Dive Safely Into These 12 Dividend Payers

If and when interest rates go up, this basket of stocks should continue to do well.

Abbvie downgraded at JP Morgan

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Stocks secure robust gains after the latest labor market snapshot breezes past expectations.

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

The drug maker continued to rally Monday.

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

AbbVie Shares Rise on Revenue Jump

AbbVie Shares Rise on Revenue Jump

Shares of AbbVie were up Friday after the company reported a big jump in revenue.

AbbVie Is Still Pointed Up, for Now

AbbVie Is Still Pointed Up, for Now

Consider raising your sell stop protection to a close below $61.

Trending Tickers: BUD, ABBV, SRCL, EXPE

Trending Tickers: BUD, ABBV, SRCL, EXPE

The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.

Buy Gilead Sciences While It's Wallowing

Buy Gilead Sciences While It's Wallowing

It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.

Take Stock of Your High-Dividend Stocks

Take Stock of Your High-Dividend Stocks

Valuations are stretched in certain names and industries, so some profit-taking appears in order.

8 Beaten-Down Post-Brexit Bargains

8 Beaten-Down Post-Brexit Bargains

These names are now oversold and are sitting at attractive prices.

Infinity Pharmaceuticals Cannot Cure Downgrades After Drug Study

Analysts cut valuation estimates after a disappointing drug study. 

Why Adding AbbVie Is the Pill to Take

Why Adding AbbVie Is the Pill to Take

With the recent pullback in the stock price, AbbVie is an attractive buy.  

Tweets on the Street: Investing in Fitness Innovation; Market Volatility Spikes

Tweets on the Street: Investing in Fitness Innovation; Market Volatility Spikes

Social media chatter on Wall Street ranged from new forms of so-called 'thematic ETFs' to spiking volatility.

Abbvie downgraded at BMO

AbbVie Gears Up for an Even Higher Run

AbbVie Gears Up for an Even Higher Run

Further near-term weakness to $60 looks like a good spot to go long. Use an appropriate risk level.